Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07187141 · ClinicalTrials.gov registry record · Phase 1
Nasal Protollin in Early Symptomatic Alzheimer's Disease
A Phase 1 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT07187141 is a Phase 1 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 16 participants.
The verdict
NCT07187141, a Phase 1 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
In this research study investigators aim to learn more about a new drug called Protollin as a possible new treatment for Alzheimer's Disease (AD). The primary goal is to assess the safety and tolerability.
Interventions
- DRUG Protollin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2021-11-18 |
| Est. Completion | 2023-02-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07187141
The ClinicalTrials.gov registry entry for NCT07187141 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Protollin is the first listed.
NCT07187141 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07187141 about?
NCT07187141 is a clinical study titled "Nasal Protollin in Early Symptomatic Alzheimer's Disease". In this research study investigators aim to learn more about a new drug called Protollin as a possible new treatment for Alzheimer's Disease (AD). The primary goal is to assess the safety and tolerability.
What is the current status of trial NCT07187141?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2021-11-18. Estimated completion is 2023-02-21.
What interventions are being tested in trial NCT07187141?
The interventions under investigation include: Protollin (DRUG).
Who is sponsoring clinical trial NCT07187141?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.